MDxHealth (NASDAQ:MDXH – Get Free Report) and Entrada Therapeutics (NASDAQ:TRDA – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, dividends and valuation.
Valuation & Earnings
This table compares MDxHealth and Entrada Therapeutics”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| MDxHealth | $107.88 million | 0.06 | -$33.52 million | ($0.72) | -0.19 |
| Entrada Therapeutics | $25.42 million | 8.09 | -$143.75 million | ($3.84) | -1.37 |
Insider and Institutional Ownership
86.4% of Entrada Therapeutics shares are held by institutional investors. 1.7% of MDxHealth shares are held by company insiders. Comparatively, 9.5% of Entrada Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Analyst Ratings
This is a breakdown of recent ratings and target prices for MDxHealth and Entrada Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| MDxHealth | 1 | 4 | 1 | 0 | 2.00 |
| Entrada Therapeutics | 1 | 2 | 4 | 0 | 2.43 |
MDxHealth presently has a consensus price target of $1.33, indicating a potential upside of 857.17%. Entrada Therapeutics has a consensus price target of $17.75, indicating a potential upside of 238.10%. Given MDxHealth’s higher possible upside, equities analysts plainly believe MDxHealth is more favorable than Entrada Therapeutics.
Profitability
This table compares MDxHealth and Entrada Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| MDxHealth | -33.46% | N/A | -24.25% |
| Entrada Therapeutics | -4,057.98% | -64.00% | -50.49% |
Risk and Volatility
MDxHealth has a beta of 1.81, suggesting that its stock price is 81% more volatile than the S&P 500. Comparatively, Entrada Therapeutics has a beta of -0.19, suggesting that its stock price is 119% less volatile than the S&P 500.
Summary
MDxHealth beats Entrada Therapeutics on 8 of the 13 factors compared between the two stocks.
About MDxHealth
MDxHealth SA (NASDAQ: MDXH) is a molecular diagnostics company focused on helping physicians make more informed decisions in cancer care. The company develops and commercializes genomic and epigenetic tests designed to support cancer detection, diagnosis, prognosis and treatment planning. MDxHealth’s portfolio has primarily centered on prostate cancer. Its ConfirmMDx test analyzes prostate tissue to help identify patients who may have clinically significant cancer despite an initially negative biopsy, while SelectMDx is a urine-based test intended to help assess the likelihood of clinically significant prostate cancer and guide decisions about biopsy.
About Entrada Therapeutics
Entrada Therapeutics, Inc. (NASDAQ:TRDA) is a biotechnology company focused on developing therapeutics designed to enter cells and address diseases caused by abnormal or missing intracellular proteins. The company’s approach is based on its Endosomal Escape Vehicle (EEV) platform, which is intended to deliver therapeutic payloads into target cells while helping them escape the endosome, a cellular compartment that can limit the effectiveness of some treatments. Entrada is developing EEV-based medicines for serious diseases, particularly genetic and neuromuscular conditions.
Receive News & Ratings for MDxHealth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MDxHealth and related companies with MarketBeat.com's FREE daily email newsletter.
